GH Peptides

PeptideSciences™ proudly offers a large selection of premium quality Growth Hormone Releasing Peptides (GHRP) and Growth Hormone Releasing Factor (GRF) peptide analogues that are assayed at a minimum purity of 99% - Guaranteed.


 

Growth Hormone Releasing Peptides are a new chemical class of GH secretagogues with a chemistry that ranges from small synthetic peptides to peptidomimetics. They release Growth Hormone in animals and humans by a unique dual and complementary action on the hypothalamus and pituitary.   Buy GHRP-2   Buy GHRP-6   Buy Hexarelin   Buy Ipamorelin

GHRP-2 (Growth Hormone Releasing Peptide-2) is a single non-glycosylated hexapeptide chain containing 6 amino acids that has been shown to stimulate Growth Hormone release. GHRP-2 is considered to be one of the most potent members of the Growth Hormone Releasing Peptide family. GHRP-2 is also known as pralmorelin and is derived from a metenkephalin peptide. It is the most potent of the family of synthetic GH stimuli known and acts via the endogenous ghrelin receptor

GHRP-6 (Growth Hormone Releasing Peptide-6) is thought to stimulate Growth hormone (GH) release at both pituitary and hypothalamic sites. A recent study in normal mice that were administered GHRP-6 showed significant differences in body composition, muscle growth, glucose metabolism, memory and cardiac function.

Ipamorelin is a pentapeptide, which displays high GH releasing potency and efficacy. Ipamorelin was identified within a series of compounds lacking the central dipeptide Ala-Trp of growth hormone releasing peptide 1 (GHRP). In vitro, ipamorelin released GH from primary rat pituitary cells with a potency and efficacy similar to GHRP-6. A pharmacological profiling clearly demonstrated that ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor. Ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation.

Hexarelin (Hexarelin Acetate) is more resistant to proteolytic degradation than GHRP-6. Recent studies have demostrated that Hexarelin is capable of causing profound GH release in normal subjects after oral, intranasal, iv, and sc administration and that chronic Hexarelin therapy results in a partial and reversible attenuation of the Growth Hormone response.The therapeutic potential of long term Hexarelin usage requires further research and investigation.

Growth hormone releasing peptides release GH in animals and humans by a unique dual and complementary action on the hypothalamus and pituitary. Although the present GHRPs are of unnatural origin, evidence by a number of investigators is gradually accumulating to support that GHRP reflects the GH-releasing action of a new natural hypothalamic hormone yet to be isolated and identified. Despite the de novo origin of GHRP, a major reason for the persistent investigation is because of the possible practical diagnostic and therapeutic value in humans as well as the potential theoretical value of new insight into the physiological regulation of GH secretion. Growth hormone releasing peptide analogues include unnatural D-amino acids, were developed for their growth hormone (GH) releasing activity and are called GH secretagogues. They lack opioid activity but are potent stimulators of GH release.

These secretagogues are distinct from growth hormone releasing hormone (GHRH) in that they share no sequence relation and derive their function through action at a completely different receptor. This receptor was originally called the GH secretagogue receptor, the hormone ghrelin is now considered the receptor's natural endogenous ligand. Therefore, these GH secretagouges act as synthetic ghrelinmimetics. Growth hormone secretagogue receptor is a G protein-coupled receptor that binds ghrelin and plays a role in energy homeostasis and regulation of body weight. Ghrelin is an appetite-regulating factor secreted from peripheral organs that is involved in regulation of energy homoeostasis via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland. A range of selective ligands for the GHSR receptor are now available and are being developed for several clinical applications. GHSR agonists have appetite-stimulating and growth hormone-releasing effects, and are likely to be useful for the treatment of muscle wasting and frailty associated with old-age and degenerative diseases. On the other hand, GHSR antagonists have anorectic effects and are likely to be useful for the treatment of obesity.